Ultimately, utilization of questionnaires assessing disease severity, such as PDAI, in concert with lab monitoring of anti‐desmoglein 1 and 3 antibodies may best allow for a holistic evaluation of disease severity, progression, and outcomes in pemphigus clinical trials. This evidence concerns the gene DSG1 and pemphigus.